Abstract
Precisely localizing therapeutic agents in neoplastic areas would greatly improve their efficacy for killing tumor cells and reduce their toxicity to normal cells. Photodynamic therapy (PDT) is a promising cancer treatment modality, and near-infrared fluorescence imaging (NIRF-I) is a sensitive and noninvasive approach for in vivo cancer detection. This review focuses on the current efforts to engineer single molecule constructs that allow these two modalities to be combined to achieve a high level of selectivity for cancer treatment. The primary component of these so called killer beacons is a fluorescent photosensitizer responsible for both imaging and therapy. By attaching other components, e.g. various DNA- or peptide-based linkers, quenchers or cancer cell-specific delivery vehicles, their primary diagnostic and therapeutic functions as well as their target specificity and pharmacological properties can be modulated. This modular design makes these agents customizable, offering the ability to assemble a few simple and often interchangeable functional modules into beacons with totally different functions. This review will summarize following three types of killer beacons: photodynamic molecular beacons, traceable beacons and beacons with built-in apoptosis sensor. Despite the rapid progress in killer beacon development, numerous challenges remain before these beacons can be translated into clinics, such as photobleaching, delivery efficiency and cancerspecificity. In this review we outline the basic principles of killer beacons, the current achievements and future directions, including possible cancer targets and different therapeutic applications.
Keywords: Near-infrared fluorescence imaging (NIRF-I), photodynamic therapy (PDT), apoptosis imaging, singlet oxygen, quenching, activation, image-guided therapy, delivery
Current Medicinal Chemistry
Title: Killer Beacons for Combined Cancer Imaging and Therapy
Volume: 14 Issue: 20
Author(s): Klara Stefflova, Juan Chen and Gang Zheng
Affiliation:
Keywords: Near-infrared fluorescence imaging (NIRF-I), photodynamic therapy (PDT), apoptosis imaging, singlet oxygen, quenching, activation, image-guided therapy, delivery
Abstract: Precisely localizing therapeutic agents in neoplastic areas would greatly improve their efficacy for killing tumor cells and reduce their toxicity to normal cells. Photodynamic therapy (PDT) is a promising cancer treatment modality, and near-infrared fluorescence imaging (NIRF-I) is a sensitive and noninvasive approach for in vivo cancer detection. This review focuses on the current efforts to engineer single molecule constructs that allow these two modalities to be combined to achieve a high level of selectivity for cancer treatment. The primary component of these so called killer beacons is a fluorescent photosensitizer responsible for both imaging and therapy. By attaching other components, e.g. various DNA- or peptide-based linkers, quenchers or cancer cell-specific delivery vehicles, their primary diagnostic and therapeutic functions as well as their target specificity and pharmacological properties can be modulated. This modular design makes these agents customizable, offering the ability to assemble a few simple and often interchangeable functional modules into beacons with totally different functions. This review will summarize following three types of killer beacons: photodynamic molecular beacons, traceable beacons and beacons with built-in apoptosis sensor. Despite the rapid progress in killer beacon development, numerous challenges remain before these beacons can be translated into clinics, such as photobleaching, delivery efficiency and cancerspecificity. In this review we outline the basic principles of killer beacons, the current achievements and future directions, including possible cancer targets and different therapeutic applications.
Export Options
About this article
Cite this article as:
Klara Stefflova , Juan Chen and Gang Zheng , Killer Beacons for Combined Cancer Imaging and Therapy, Current Medicinal Chemistry 2007; 14 (20) . https://dx.doi.org/10.2174/092986707781389655
DOI https://dx.doi.org/10.2174/092986707781389655 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Genitourinary Complications of Diabetes Mellitus: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer
Clinical Cancer Drugs IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Oral Cavity-Associated Immune System: What is New?
Current Immunology Reviews (Discontinued) The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy
Current Clinical Pharmacology Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
Current Cancer Drug Targets Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Apoptosis in Physiological and Pathological Skin: Implications for Therapy
Current Molecular Medicine The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy